XPANSIV
23.3.2022 14:23:04 CET | Business Wire | Press release
Xpansiv, the global marketplace for ESG commodities, today announced the launch of Digital Crude Oil™ (DCO), the latest addition to the Xpansiv Digital Fuels™ Program . DCO units registered on the Xpansiv DF Registry enable markets to differentiate crude oil based on greenhouse-gas emissions and ESG performance.
The inaugural DCOs will be registered from Lundin Energy ’s North Sea production, representing carbon intensity and other key environmental attributes for individual barrels of oil.
“This is a critical moment of confluence between two paradigm shifts in global energy, digitization and decarbonization,” said Xpansiv CEO Joe Madden. “The energy transition will be driven by greater data transparency, so crude oil producers like Lundin Energy with improved ESG performance are rewarded with a clear price signal. The Xpansiv platform provides the financial infrastructure—from source data to market outcomes—that enables this shift in the valuation of global commodities.”
“The time has come for a differentiated market for responsibly produced oil and gas,” said Lundin Energy CFO Teitur Poulsen. “We have already sold certified, carbon-neutrally produced crude cargoes, which indicates the demand signals are real. Certification and traceability are key to creating a credible market for responsibly produced hydrocarbons, and we’re pleased to work with Xpansiv to help develop this market in the right way.”
Certification-company Intertek has also joined the Xpansiv Digital Fuels Program ecosystem as DCO-certification partner, adding another source of data-quality assurance, carbon-intensity benchmarking, and independent certifications.
Xpansiv created the Digital Fuels Program to support the creation, issuance, registration, management, trading, and retirement of encrypted digital twins that include the environmental attributes of fuels. The program includes a burgeoning network of energy producers, data refineries, monitoring networks, lifecycle assessments, standards and certification organizations, and downstream market participants—all operating under a Governance Framework that specifies data quality and management protocols, as well as full lifecycle requirements for these new digital assets.
Similar to DNGs, DCOs bring transparency and precision to measuring the ESG impacts of crude-oil production based on immutable data, auditable from source to market. “Trust from all stakeholders in the sustainability journey will only happen with total transparency, and Intertek is proud to be a part of the energy industry’s journey,” said Intertek SVP Total Energy Malissa Boudreaux.
In September, Xpansiv announced the first transaction of Digital Natural Gas ® (DNG™ ) through its DF Registry. Since then, more than 2,000 Methane Performance Certificates (MPCs) have traded, with daily price assessments provided by S&P Global Platts. DNG empowers downstream customers to demonstrate quantified progress in meeting methane-reduction commitments and net-zero goals based on empirical data. Producers are uploading approximately 1 billion cubic feet of natural gas data onto the Xpansiv platform every day to create DNG.
“Digital Crude Oil again demonstrates how the Xpansiv platform can ingest and contextualize complex data from multiple sources according to rigorous governance rules,” said Xpansiv Sustainability Director Jeff Cohen. “As a result, we can now differentiate raw-material inputs to global supply chains based on environmental performance innovations—information that was previously invisible to markets.”
About Xpansiv
Xpansiv is the global marketplace for ESG-inclusive commodities. These Intelligent Commodities bring transparency and liquidity to markets, empowering participants to value energy, carbon, and water to meet the challenges of an information-rich, resource-constrained world. The company’s main business units include CBL , the largest spot exchange for ESG commodities, including carbon, renewable energy certificates, and Digital Natural Gas; H2OX , the leading spot exchange for water; XSignals , which provides end-of-day and historical market data; and EMA , the leading multi-registry portfolio management system for all ESG-inclusive commodities. Xpansiv is the digital nexus where ESG and price signals merge. Xpansiv.com
About Lundin Energy
Lundin Energy is an experienced Nordic oil and gas company that explores for, develops, and produces resources economically, efficiently, and responsibly. We focus on value creation for our shareholders and wider stakeholders through three strategic pillars: Resilience, Sustainability, and Growth. Our high-quality, low-cost assets mean we are resilient to oil-price volatility, and our organic growth strategy, combined with our sustainable approach and commitment to decarbonisation, firmly establishes our leadership role in a lower carbon energy future. lundin-energy.com
About Intertek
Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories and offices in more than 100 countries delivers innovative and bespoke Assurance, Testing, Inspection, and Certification solutions for our customers' operations and supply chains. Intertek Total Quality Assurance expertise—delivered consistently with precision, pace, and passion—enables our customers to power ahead safely. intertek.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom